Citations

Showing 10 of 108104 citations.

A Prognostic Index to Identify the Risk of Developing Depression Symptoms Among U.S. Medical Students Derived From a National, Four-Year Longitudinal Study
Wittlin, Natalie M. , Yeazel, Mark W. , Burke, Sara E. , Cunningham, Brooke A. , Ryn, Michelle van , Dyrbye, Liselotte N. , van Ryn, Michelle , Hardeman, Rachel R. , Herrin, Jeph , Dovidio, John F. , Phelan, Sean M. , Shanafelt, Tait D.

Mayo Clinic

Academic Medicine | September 5, 2018 | Volume: 94 | Issue: 2 | Pages: 217-226

10.1097/acm.0000000000002437 | PMID 30188367 Get It

Purpose To determine baseline individual and school-related factors associated with increased risk of developing depression symptoms by year four (Y4) of medical school, and to develop a prognostic index that stratifies risk of developing depression symptoms (Depression-PI) among medical students. Method The authors analyzed data from 3,743 students (79% of 4,732) attending 49 U.S. medical schools who completed baseline (2010) and Y4 (2014) surveys. Surveys included validated scales measuring depression, stress, coping, and social support. The authors collected demographics and school characteristics and conducted multivariate analysis to identify baseline factors independently associated with Y4 depression symptoms. They used these factors to create a prognostic index for developing depression. They randomly divided the data into discovery (n = 2,455) and replication (n = 1,288) datasets and calculated c statistics ( c ). Results The authors identified eight independent prognostic factors for experiencing depression symptoms during training within the discovery dataset: age; race; ethnicity; tuition; and baseline depression symptoms, stress, coping behaviors, and social support. The Depression-PI stratified four risk groups. Compared with the low risk group, those in the intermediate, high, and very high risk groups had an odds ratio of developing depression of, respectively, 1.75, 3.98, and 9.19 ( c = 0.71). The replication dataset confirmed the risk groups. Conclusions Demographics; tuition; and baseline depression symptoms, stress, coping behaviors, and social support are independently associated with risk of developing depression during training among U.S. medical students. By stratifying students into four risk groups, the Depression-PI may allow for a tiered primary prevention approach.
Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations
Kornstein, Susan G., Joffe, Hadine , Freeman, Ellen W. , Athappilly, Geena, Rubin, Leah H. , Koleva, Hristina , Cohen, Lee S. , Bobo, William V. , Maki, Pauline M. , Bromberger, Joyce T. , Soares, Cláudio N.

Mayo Clinic

Journal of Women's Health | September 5, 2018 | Volume: 28 | Issue: 2 | Pages: 117-134

10.1089/jwh.2018.27099.mensocrec | PMID 30182804 Get It

There is a new appreciation of the perimenopause—defined as the early and late menopause transition stages as well as the early postmenopause—as a window of vulnerability for the development of both depressive symptoms and major depressive episodes. However, clinical recommendations on how to identify, characterize and treat clinical depression are lacking. To address this gap, an expert panel was convened to systematically review the published literature and develop guidelines on the evaluation and management of perimenopausal depression. The areas addressed included: (1) epidemiology; (2) clinical presentation; (3) therapeutic effects of antidepressants; (4) effects of hormone therapy; and (5) efficacy of other therapies ( e.g. , psychotherapy, exercise, and natural health products). Overall, evidence generally suggests that most midlife women who experience a major depressive episode during the perimenopause have experienced a prior episode of depression. Midlife depression presents with classic depressive symptoms commonly in combination with menopause symptoms ( i.e. , vasomotor symptoms, sleep disturbance), and psychosocial challenges. Menopause symptoms complicate, co-occur, and overlap with the presentation of depression. Diagnosis involves identification of menopausal stage, assessment of co-occurring psychiatric and menopause symptoms, appreciation of the psychosocial factors common in midlife, differential diagnoses, and the use of validated screening instruments. Proven therapeutic options for depression ( i.e. , antidepressants, psychotherapy) are the front-line treatments for perimenopausal depression. Although estrogen therapy is not approved to treat perimenopausal depression, there is evidence that it has antidepressant effects in perimenopausal women, particularly those with concomitant vasomotor symptoms. Data on estrogen plus progestin are sparse and inconclusive.
Heterogeneity of programmed death‐ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences
Terra, Simone , Mansfield, Aaron S. , Vrana, Julie A., Roden, Anja C. , Terra, Simone B S P, Mansfield, Aaron S

Mayo Clinic

Histopathology | September 5, 2018 | Volume: 74 | Issue: 2 | Pages: 364-367

10.1111/his.13750 | PMID 30182429 Get It

Pivotal Role of Intraoperative Transesophageal Echocardiography for Detecting Iatrogenic Aortic Regurgitation due to Cardiac Catheterization
Kolla, Kantha R. , Larsen, Carolyn , Click, Roger L., Chaliki, Hari P. , Maltais, Simon, Larsen, Carolyn M

Mayo Clinic

Korean Circulation Journal | September 5, 2018 | Volume: 48 | Issue: 12 | Pages: 1160

10.4070/kcj.2018.0136 | PMID 30403021 Get It

Anterior Cranial Fossa Dural Arteriovenous Fistula Presenting as Recurrent Multifocal Lobar Intracerebral Hemorrhages: A Case Report
Johnson, Stephen A. , Cox, Benjamin C. , Ho, Mai‐Lan , Murphy, Meghan E. , Johnson, Stephen Abraham, Cox, Benjamin, Murphy, Meghan, Ho, Mai-Lan , Johnson, Stephen A , Ho, Mai Lan, Scharf, Eugene

Mayo Clinic

The Neurohospitalist | September 4, 2018 | Volume: 9 | Issue: 2 | Pages: 109-112

10.1177/1941874418797797 | PMID 30915190 Get It

We report a unique case and presentation of a 77-year-old man with atrial fibrillation who presented with complex imaging features, including bifrontal cerebral hematomas that progressed to multifocal macro- and microhemorrhages, vasogenic edema, and cortical/meningeal enhancement. Cerebrospinal fluid analysis was only remarkable for a protein elevation of 65 mg/dL. Leptomeningeal vessel biopsy failed to demonstrate evidence of amyloid angiopathy but did show concentric obstructive intimal fibroplasia, suggestive of chronic venous congestion. Conventional cerebral angiography showed a Cognard type IV dural arteriovenous fistulae fed by bilateral ethmoidal arteries draining directly into ectatic cortical veins. A chronic occlusion of the anterior third of the superior sagittal sinus was also noted. The fistula was successfully surgically obliterated via an uncomplicated left frontal craniotomy approach. After rehabilitation therapy, he was discharged home with a modified Rankin Scale score of 3. Because effective treatment exists, this case underscores the importance of identifying this rare etiology of intracerebral hemorrhage and pursuing adequate workup.
Common DNA Variants Accurately Rank an Individual of Extreme Height
Sexton, Corinne E. , Ebbert, Mark , Miller, R.H. , Ferrel, Meganne , Tschanz, Jo Ann T., Corcoran, Christopher, Initiative, Alzheimer’s Disease Neuroimaging, Ridge, Perry G. , Kauwe, John S. K. , Ebbert, Mark T W , Miller, Ryan H.

Mayo Clinic

International Journal of Genomics | September 4, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/5121540 | PMID 30255029 Get It

Polygenic scores (or genetic risk scores) quantify the aggregate of small effects from many common genetic loci that have been associated with a trait through genome-wide association. Polygenic scores were first used successfully in schizophrenia and have since been applied to multiple phenotypes including multiple sclerosis, rheumatoid arthritis, and height. Because human height is an easily-measured and complex polygenic trait, polygenic height scores provide exciting insights into the predictability of aggregate common variant effect on the phenotype. Shawn Bradley is an extremely tall former professional basketball player from Brigham Young University and the National Basketball Association (NBA), measuring 2.29 meters (7 ′ 6 ″ , 99.99999th percentile for height) tall, with no known medical conditions. Here, we present a case where a rare combination of common SNPs in one individual results in an extremely high polygenic height score that is correlated with an extreme phenotype. While polygenic scores are not clinically significant in the average case, our findings suggest that for extreme phenotypes, polygenic scores may be more successful for the prediction of individuals.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Rhee, Frits van , Voorhees, Peter M. , Srkalović, Gordan , Ide, Makoto , Munshi, Nikhil C. , Schey, Stephen, Streetly, Matthew , Pierson, Sheila K. , Partridge, Helen , Shilling, Dustin, Stone, Katie , Greenway, Amy D, Ruth, Jason R., Lechowicz, Mary Jo , Jayanthan, Raj , Leitch, Heather A. , Pemmaraju, Naveen , Chadburn, Amy , Lim, Megan S. , Elenitoba‐Johnson, Kojo S.J. , Goodman, Aaron M. , Hoffmann, Christian , Zinzani, Pier Luigi , Ferrero, Simone , Terriou, Louis , Simpson, David , Rossi, Jean‐François, Yoshizaki, Kazuyuki , Oksenhendler, Éric , van Rhee, Frits , Wong, Raymond S M , Casper, Corey , Fajgenbaum, David C , Ferrero, Simone , Zinzani, Pier Luigi , Dispenzieri, Angela , Fosså, Alexander , Partridge, Helen L., Mukherjee, Sudipto , Chandrakasan, Shanmuganathan , Jaffe, Elaine S. , Krymskaya, Vera P. , Sato, Yasuharu , Wong, Raymond , Rossi, Jean‐François , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C. , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | September 4, 2018 | Volume: 132 | Issue: 20 | Pages: 2115-2124

10.1182/blood-2018-07-862334 | PMID 30181172 Get It

Abstract Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.
A method to reduce variability in scoring antibody-mediated rejection in renal allografts: implications for clinical trials - a retrospective study
Smith, Byron H. , Cornell, Lynn D. , Cortese, Cherise , Geiger, Xochiquetzal J., Alexander, Mariam P., Ryan, Margaret , Park, Walter D. , Morales-Álvarez, Martha Catalina , Kremers, Walter K. , Stegall, Mark D. , Smith, Byron , Geiger, Xochiquetzal, Park, Walter, Morales Alvarez, Martha Catalina, Stegall, Mark, Stegall, Mark D , Park, Walter , Cornell, Lynn , Kremers, Walter K , Smith, Maxwell L. , Schinstock, Carrie A.

Mayo Clinic

Transplant International | September 4, 2018 | Volume: 32 | Issue: 2 | Pages: 173-183

10.1111/tri.13340 | PMID 30179275 Get It

Progression of Emergency Medicine Resident Patient Experience Scores by Level of Training
Walker, Laura , Colletti, James E., Bellolio, Fernanda , Nestler, David M. , Walker, Laura E , Bellolio, M Fernanda, Bellolio, M Fernanda

Mayo Clinic

Journal of Patient Experience | September 4, 2018 | Volume: 6 | Issue: 3 | Pages: 210-215

10.1177/2374373518798098 | PMID 31535009 Get It

Background: Patient satisfaction surveys are vital to measuring a patient’s experience of care. How scores of patients managed by emergency medicine (EM) residents change as residents progress through training is not known. Objectives: To evaluate whether EM residents’ patient satisfaction scores improve as residency training progresses, similar to clinical skill improvement. Methods: A retrospective cross-sectional study evaluated the correlation of patient satisfaction scores with EM resident year of training from 2015 through 2017. We evaluated for a change in score over time for the 4 “physician questions” and the “overall” score. Results: We evaluated 1684 Press Ganey surveys linked to 40 EM resident physicians during the study period. The mean top box scores for the 4 physician questions (concern for comfort [ P = .72], courtesy [ P = .55], informative about treatment [ P = .46], and listening [ P = .91]) and overall assessment of emergency department care ( P = .51) were not significantly improved over the course of resident. Conclusion: We did not observe a difference in EM residents’ patient experience scores as their level of training progressed. Comprehensive patient experience training for residents might be needed.
Randomized Sham-Controlled Trial of Navigated Repetitive Transcranial Magnetic Stimulation for Motor Recovery in Stroke
Harvey, Richard L. , Dunning, Kari , Fregni, Felipe , Stein, Joel , Laine, Jarmo , Rogers, Lynn M., Vox, Ford, Durand-Sanchez, Ana, Goldstein, Larry B. , Kinney, Carolyn L. , Investigators*, on behalf of the NICHE Trial, Ryan, Shirley, Morales-Quezada, León , Labar, Douglas, Kappy, Carlyn R., PRATT, W. HOWARD, Kinney, Carolyn , Edwards, Dylan J. , Bockbrader, Marcia A. , Francisco, Gerard E. , Liu, Charles Y. , Investigators*, on behalf of the NICHE Trial, Worthen‐Chaudhari, Lise , Schambra, Heidi M. , Kissela, Brett , Pratt, Whitney

Mayo Clinic

Stroke | September 4, 2018 | Volume: 49 | Issue: 9 | Pages: 2138-2146

10.1161/strokeaha.117.020607 | PMID 30354990 Get It

Background and Purpose― We aimed to determine whether low-frequency electric field navigated repetitive transcranial magnetic stimulation to noninjured motor cortex versus sham repetitive transcranial magnetic stimulation avoiding motor cortex could improve arm motor function in hemiplegic stroke patients when combined with motor training. Methods― Twelve outpatient US rehabilitation centers enrolled participants between May 2014 and December 2015. We delivered 1 Hz active or sham repetitive transcranial magnetic stimulation to noninjured motor cortex before each of eighteen 60-minute therapy sessions over a 6-week period, with outcomes measured at 1 week and 1, 3, and 6 months after end of treatment. The primary end point was the percentage of participants improving ≥5 points on upper extremity Fugl-Meyer score 6 months after end of treatment. Secondary analyses assessed changes on the upper extremity Fugl-Meyer and Action Research Arm Test and Wolf Motor Function Test and safety. Results― Of 199 participants, 167 completed treatment and follow-up because of early discontinuation of data collection. Upper extremity Fugl-Meyer gains were significant for experimental ( P <0.001) and sham groups ( P <0.001). Sixty-seven percent of the experimental group (95% CI, 58%–75%) and 65% of sham group (95% CI, 52%–76%) improved ≥5 points on 6-month upper extremity Fugl-Meyer ( P =0.76). There was also no difference between experimental and sham groups in the Action Research Arm Test ( P =0.80) or the Wolf Motor Function Test ( P =0.55). A total of 26 serious adverse events occurred in 18 participants, with none related to the study or device, and with no difference between groups. Conclusions― Among patients 3 to 12 months poststroke, goal-oriented motor rehabilitation improved motor function 6 months after end of treatment. There was no difference between the active and sham repetitive transcranial magnetic stimulation trial arms. Clinical Trial Registration― URL: https://www.clinicaltrials.gov . Unique identifier: NCT02089464.